| pubmed-article:17763951 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:17763951 | lifeskim:mentions | umls-concept:C0205054 | lld:lifeskim |
| pubmed-article:17763951 | lifeskim:mentions | umls-concept:C1280500 | lld:lifeskim |
| pubmed-article:17763951 | lifeskim:mentions | umls-concept:C0596570 | lld:lifeskim |
| pubmed-article:17763951 | lifeskim:mentions | umls-concept:C1524081 | lld:lifeskim |
| pubmed-article:17763951 | lifeskim:mentions | umls-concept:C1517004 | lld:lifeskim |
| pubmed-article:17763951 | pubmed:issue | 3 | lld:pubmed |
| pubmed-article:17763951 | pubmed:dateCreated | 2008-2-26 | lld:pubmed |
| pubmed-article:17763951 | pubmed:abstractText | The renin-angiotensin system is suggested to be important in liver fibrogenesis. It induces hepatic stellate cell proliferation and up-regulates transforming growth factor beta-1 (TGF-beta1) expression. Matrix metalloproteinase-2 (MMP-2) is involved in extracellular matrix remodelling. Fibrosis, a consequence of most chronic liver diseases, may be the result of a disturbed balance between fibrogenesis and fibrolysis. The aim of this study was to investigate the effect of enalapril on liver fibrogenesis induced in rats by bile-duct ligation. Forty-seven rats were divided into two groups: bile-duct ligated (BDL) (n = 24) and BDL + enalapril (n = 23). Fibrosis was evaluated by the Knodell scoring system, and TGF-beta1 and MMP-2 were assessed with immunohistochemistry at the second, fourth and sixth weeks after bile-duct ligation. In the BDL group, TGF-beta1 increased by the second week and this increase continued through weeks 4 and 6. In the BDL + enalapril group, TGF-beta1 was significantly lower than the other group (P < 0.05). MMP-2 progressively decreased after week 2 in the BDL group. In the BDL + enalapril group, MMP-2 was significantly higher than the BDL group at the fourth and sixth weeks. These results suggest that enalapril reduces the liver tissue TGF-beta1 and has an ameliorating effect on the fibrosis markers TGF-beta1 and MMP-2. | lld:pubmed |
| pubmed-article:17763951 | pubmed:language | eng | lld:pubmed |
| pubmed-article:17763951 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17763951 | pubmed:citationSubset | AIM | lld:pubmed |
| pubmed-article:17763951 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17763951 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17763951 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17763951 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17763951 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:17763951 | pubmed:month | Mar | lld:pubmed |
| pubmed-article:17763951 | pubmed:issn | 0163-2116 | lld:pubmed |
| pubmed-article:17763951 | pubmed:author | pubmed-author:YönemOzlemO | lld:pubmed |
| pubmed-article:17763951 | pubmed:author | pubmed-author:KoyuncuAyhanA | lld:pubmed |
| pubmed-article:17763951 | pubmed:author | pubmed-author:AriciSemaS | lld:pubmed |
| pubmed-article:17763951 | pubmed:author | pubmed-author:TürkayCanselC | lld:pubmed |
| pubmed-article:17763951 | pubmed:author | pubmed-author:KanbayMehmetM | lld:pubmed |
| pubmed-article:17763951 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:17763951 | pubmed:volume | 53 | lld:pubmed |
| pubmed-article:17763951 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:17763951 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:17763951 | pubmed:pagination | 789-93 | lld:pubmed |
| pubmed-article:17763951 | pubmed:meshHeading | pubmed-meshheading:17763951... | lld:pubmed |
| pubmed-article:17763951 | pubmed:meshHeading | pubmed-meshheading:17763951... | lld:pubmed |
| pubmed-article:17763951 | pubmed:meshHeading | pubmed-meshheading:17763951... | lld:pubmed |
| pubmed-article:17763951 | pubmed:meshHeading | pubmed-meshheading:17763951... | lld:pubmed |
| pubmed-article:17763951 | pubmed:meshHeading | pubmed-meshheading:17763951... | lld:pubmed |
| pubmed-article:17763951 | pubmed:meshHeading | pubmed-meshheading:17763951... | lld:pubmed |
| pubmed-article:17763951 | pubmed:meshHeading | pubmed-meshheading:17763951... | lld:pubmed |
| pubmed-article:17763951 | pubmed:meshHeading | pubmed-meshheading:17763951... | lld:pubmed |
| pubmed-article:17763951 | pubmed:meshHeading | pubmed-meshheading:17763951... | lld:pubmed |
| pubmed-article:17763951 | pubmed:meshHeading | pubmed-meshheading:17763951... | lld:pubmed |
| pubmed-article:17763951 | pubmed:year | 2008 | lld:pubmed |
| pubmed-article:17763951 | pubmed:articleTitle | Effect of angiotensin-converting enzyme inhibition on experimental hepatic fibrogenesis. | lld:pubmed |
| pubmed-article:17763951 | pubmed:affiliation | Department of Gastroenterology, Faculty of Medicine, Fatih University, Ankara, Turkey. | lld:pubmed |
| pubmed-article:17763951 | pubmed:publicationType | Journal Article | lld:pubmed |
